Infinity Pharmaceuticals Inc. Reaches New 12-Month Low at $14.36 (INFI)
Infinity Pharmaceuticals (NASDAQ:INFI)’s share price reached a new 52-week low on Wednesday, Analyst Ratings Network.com reports. The company traded as low as $14.36 and last traded at $15.27, with a volume of 954,747 shares traded. The stock had previously closed at $16.01.
A number of research firms have recently commented on INFI. Analysts at William Blair initiated coverage on shares of Infinity Pharmaceuticals in a research note to investors on Monday, September 23rd. They set a “market perform” rating and a $21.00 price target on the stock. Separately, analysts at Goldman Sachs Group Inc. raised their price target on shares of Infinity Pharmaceuticals from $20.00 to $22.00 in a research note to investors on Wednesday, September 18th. Finally, analysts at Morgan Stanley cut their price target on shares of Infinity Pharmaceuticals from $47.00 to $25.00 in a research note to investors on Monday, August 19th. They now have a “hold” rating on the stock. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $32.25.
Infinity Pharmaceuticals has a 52 week low of $15.45 and a 52 week high of $50.51. The stock has a 50-day moving average of $19.02 and a 200-day moving average of $25.32. The company’s market cap is $728.4 million.
Infinity Pharmaceuticals (NASDAQ:INFI) last released its earnings data on Thursday, August 8th. The company reported ($0.68) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.62) by $0.06. During the same quarter last year, the company posted ($0.54) earnings per share. On average, analysts predict that Infinity Pharmaceuticals will post $-2.89 earnings per share for the current fiscal year.
Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.